Objective: The objective of this paper is to review experience in prevention of mother-to-child transmission (PMTCT) of HIV in Georgia. Background: PMTCT is one of the strategic priorities in Georgia. The first case of HIV infection in pregnant women was reported in 1999. Starting 2005 the National Programme on PMTCT became operational. Fifty eight women (90.6%) acquired infection through heterosexual contact. None of the HIV positive women reported intravenous injection of illicit drugs. The majority of the HIV infected pregnant women had one sexual partner (90.6%). Of children delivered by 51 positive partners 41(80%) were infected through injecting drugs intravenously and 10 (20%) persons through heterosexual contacts.
INTRODUCTION
The HIV pandemic is one of the most serious health crises in human history. The Joint United Nations Programme on AIDS (UNAIDS) and the World Health Organization (WHO) estimate that approximately 33.2 million people were living with HIV worldwide in 2007, including 2.5 million children under 15. A disproportionate burden has been placed on women and children, who in many settings continue to experience high rates of new HIV infections and of HIV-related illnesses and death. In 2005 alone, an estimated 420,000 children were newly infected with HIV (1) .
Georgia -the independent nation formerly part of the Soviet Union -is classified as having a low-prevalence HIV epidemic with an estimated prevalence of 0.09%. The first case of HIV infection in Georgia was reported in 1989. As of December 2007, a total of 1,472 HIV/AIDS cases have been registered officially in Georgia, including 38 children under 15. The estimated number of HIV/AIDS cases is 3,000.
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV: THE GEORGIAN EXPERIENCE
Similarly to other Newly Independent States (NIS) of the Former Soviet Union (FSU), Georgia's HIV epidemic is strongly associated with injection drug use (IDU) accounting for approximately 60% of all reported cases. However over the last several years heterosexual route is gaining on importance, with nearly 33% of cases attributed to heterosexual transmission. At the same time, annual number of newly reported HIV infections among females has risen each year and the number has almost tripled over the last three years (2005) (2006) (2007) (Fig. 1) .
Despite HIV low prevalence, Georgia is believed to be at risk for an imminent epidemic spread of HIV due to widespread injecting drug use, high rates of sexually transmitted infections (STI) and by hepatitis B and C, which share common routes of transmission and by intense population movement between neighboring high-prevalence countries such as Ukraine and Russia.
Georgia was one of the countries in the NIS that immediately reacted to the epidemic in early 1990s. National efforts have led to a number of key achievements: establishment of HIV/AIDS service organizational structures, development of legal, policy and programme friendly environment. There is mandatory notification of HIV infection. All identified cases are referred to the Infectious Diseases, AIDS and Clinical Immunology Research Center (IDACIRC) for HIV-related care. Diagnostics and treatment of AIDS patients are provided at the highest attainable standards. The treatment services are provided at this Center and two regional treatment facilities coordinated by IDACIRC.
Since 2004 Georgia has demonstrated substantial progress in addressing HIV epidemic, especially in the scaling-up Antiretroviral Therapy (ART) as result of strengthened resource allocation from the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM). Through financial support of GFATM and under coordination of IDACIRC, Georgia first among NIS ensured universal access to ART, which along with provision of antiretroviral drugs (ARV) also implies comprehensive clinical and laboratory care of all People Living with HIV/AIDS (PLHA).
Mother-to-child transmission (MTCT) of HIV remains a major public health problem worldwide, especially in developing countries. Prevention of mother-to-child transmission (PMTCT) of HIV is one of the major strategic priorities as defined by the National Strategic Plan of Action (NSPA) of Georgia. HIV can be transmitted from an infected mother to her child in utero, during delivery, and postnatally through breastfeeding. Implementation of effective PMTCT strategies in developed countries reduced transmission rates to less than 2%, while the rate of new infections in children remains high in developing countries (2) (3) (4) (5) .
In PMTCT services are provided free of charge and are supported by the Government of Georgia, Vishnevskaya-Rostropovich Foundation (VRF) and GFATM. In general all pregnant women with confirmed HIV diagnosis are involved in the PMTCT programme funded by the GFATM and being implemented by the IDACIRC in partnership with Georgian Obstetricians and Gynecologists Association (GOGA). IDACIRC has an experience of providing PMTCT services to HIV-infected women since 1999, when the first case of HIV was detected in pregnant woman. The comprehensive approach to reducing mother-to-child transmission is based on existing evidence (6-12) and includes: provision of prophylactic ART; counselling and support for delivery and infant feeding; HIV-related care and ART of mother and infant, including cotrimoxazole prophylaxis.
MATERIALS AND METHODS
There are 116 VCT Centers for pregnant women in Georgia. VCT centers distribution is the following: 19 of them are located at Women Health Centers, 88 in maternity hospitals, and other 9 VCT centers are allocated in different regional hospitals of Georgia.
Voluntary Counselling and Testing
To insure high quality VCT service availability, "Global Fund to Fight HIV/AIDS, TB and Malaria" (GFATM), IDACIRC together with Georgian Obstetric and Gynecologist Association (GOGA) trained VCT specialists for Maternity houses and WHC's. Training materials were developed in Georgian language and based on WHO recommendations.
According to the National PMTCT protocol, all first time attending pregnant women were offered VCT. VCT was provided according to the WHO recommendations. One to one as well as couple pre-test counselling included identification of risk behavioural factors, knowledge on HIV/AIDS, importance of HIV testing and interpretation of test results, prevention interventions etc. Testing on HIV/AIDS was based on identification of HIV antibodies by screening method, using high sensitive and specific rapid/simple tests. Detection of HIV antibodies was performed using Rapid Anti-HIV (1&2) Test InTec PRODUCTS, INC. By protocol, all reactive samples were sent for confirmation (by Western Blot method) to IDACIRC.
Confirmation of HIV test results was done by retesting of sample using Vironostica HIV Uni-Form II Ag/Ab. bioMerieux, The Netherlands by ELISA with further confirmation by Western Blot method using HIV BLOT 2.2 Western Blot Assay.
After confirmation, results were sent back to the counsellors for post-test consultation. Post-test counselling was held in the same institution. All HIV-positive women were referred to IDACIRC for follow-up, psychological support and clinical/prophylactic interventions.
ARV Prophylaxis
Management of HIV-positive pregnant women was provided according to the national PMTCT guideline. According to guideline, PMTCT was initiated from the 28th week of gestation for all HIV-positive ARV naive pregnant women (without clinical and laboratory indications for HAART). ARV regimens were the following: 1. monotherapy with AZT or 2. combination of AZT+3TC, or 3. combination of AZT+ 3TC+ SQV/rtv. AZT+ 3TC+ SQV/rtv-based drug regimen was considered as preferable and cost-effective regiment.
In case of AZT monotherapy or delayed diagnosis of HIV, NVP tablet was administered 2-3 hours before the delivery. Caesarean section was performed at the 38th week of gestation. I.v. AZT was administered during delivery. After delivery ARV treatment was stopped.
In case pregnant women is HIV-positive and ARV treatment [symptomatic HIV infection with relevant symptoms, lower CD4 count (CD4 count < 200/mm 3 ) or CD4 is 201-350/mm 3 and viral load is more than 100,000 copies/ml] was introduced in the 2nd trimester of pregnancy, EFV was excluded from combination. If pregnant women already were on ART, EFV was switched to NVP.
All newborns born by HIV-positive mothers were given appropriate ARV treatment consisting of AZT+NVP. Dosage and prophylaxis duration in newborns were defined according to the national and WHO guidelines. All HIV-positive mothers were recommended not to breast-feed infant despite the ARV regimen.
In adition, PMTCT programme considered also cotrimoxazole PCP prophylaxis for children of HIV-positive mothers.
Infants HIV Status Detection
All infants, who were born from HIV positive mothers, were screened for HIV infection twice using virological test (HIV DNA PCR) at 48 hours and 4 months of age. Blood samples from the umbilical cord were not used for diagnostic evaluations because of potential contamination with maternal blood. Blood samples collected at the maternity house by the skilled professional were immediately delivered to the IDACIRC for investigation.
Till 2006, HIV-1 RNA in plasma was measured by commercially available quantitative Polymerase Chain Reaction (PCR) method (AMPLICOR HIV-1 MONITOR Test, version 1.5, Hoffmann-La Roche, Inc.) and run according to the protocol of the manufacturer. Since 2006 The COBAS TaqMan HIV-1 test (real time PCR) was used for quantification of HIV-1 RNA in hunam EDTA plasma, using the High Pure System Viral Nucleic Acid Kit for manual specimen preparation and the COBAS TaqMan 48 Analyzer for automated amplification and detection. The test can quantify HIV-1 RNA over range of 40-10.000,000 copies/ml.
A positive virological test (usually DNA) at 48 hours of age presumably meant that the infant was "probably HIV-infected" and was retested again with virological test using separate specimen for confirmation as soon as possible. Only the second HIV positive test can confirm infant´s HIV infection. A negative result at this stage suggested an undetermined status.
A child with positive virological test result at the 4th month of age was retested again using separate specimen for confirmation in order to indicate whether the infant was HIV-infected and should be clinically evaluated to develop a management strategy. Negative HIV test result pointed to HIV-negative status.
Data Collection
Data collection was made retrospectively, using information from IDACIRC National HIV/AIDS Data Base, VRF for the period 1999-2007.
Medical charts and case investigation records were reviewed for HIV-positive women (age, educational level, employment, marital status, risk behavior, transmission mode, clinical and laboratory markers).
RESULTS
To facilitate full-scale implementation of the PMTCT programme IDACIRC and GOGA trained 670 professionals working in antenatal health services in 2004-2005 to ensure high quality VCT services at the antenatal clinics throughout the country.
In 2006, 42,430 pregnant women agreed and received VCT services (total number of deliveries in 2006: 48,181). Fourteen women were found to be HIV-positive, thus the prevalence of HIV among pregnant women availing VCT services was 0.03%.
A total of 69 pregnancies in 64 HIV-infected women were reported in Georgia from 1999 to 2007. Women were identified through HIV case investigation, EGPAF project and National Programme on PMTCT.
Majority of women were falling into the age group of 20 to 30 at the time of HIV diagnosis [mean age 27.3 (standard deviation 6.4; range 17-49)], had a high school level of education (62.5%), were unemployed (76.6%), and were married (82.8) ( Table 1) . Nine women were internally displaced persons.
Distribution of HIV positive pregnant women by regions of Georgia correlated with HIV prevalence in these regions, with most of cases reported from the capital city of Tbilisi (Fig. 2) .
Fifty eight women (90.6%) acquired infection through heterosexual contact, in 6 cases (9.4%) mode of transmission was not ascertained. None of the HIV-positive women reported intravenous injection of illicit drugs. The majority of the HIVinfected pregnant women had one sexual partner (90.6). There was low demand and use of condoms and contraceptives in this population. With regard to sexual partners, 51 (69.7%) partners were HIV-positive, 6 (9.4%) were HIV-negative, in 7 (10.9%) cases partner HIV status was not detected. Among 51 positive partners 41 (80%) were infected through injecting drugs intravenously and 10 (20%) persons through heterosexual contacts ( Table 2 ).
All HIV-positive pregnant women admitted at the IDACIRC underwent the comprehensive clinical and laboratory investigations. CD4+ cell count in 36 cases of pregnancy was more then 500 cells/mm 3 , in 27 cases 200-500 cells/mm 3 , and 6 cases were below 200 cells/mm 3 . AIDS was determined in 6 cases of pregnancy. Viral load was above 1,000 copies/ml in 62 cases and below this level in 7 cases. Viral load did not change the PMTCT design. Anemia was frequent problem in HIV-positive pregnant women in Georgia. Main reason of anemia was iron deficiency. Chronic hepatitis C and/or B co-infection was revealed in 6 cases of pregnancy. Among them 4 were co-infected with hepatitis C and two were both HBsAg and anti-HCV-positive. Co-infection with lung tuberculosis was detected in 2 cases. None of the patients was infected with other sexually transmitted (syphilis and/or gonorrhea) disease (Table 3) .
Throughout the period 1999-2007 prophylactic strategy in HIV-positive pregnant women was tailored individually according to the gestation age, HIV disease stage, availability of ARVs, patient's desire to receive prophylaxis etc.
14 pregnant women received PMTCT services only partially. The reason was: late HIV diagnosis, limited access to ARV (from 1999 till 2004); refusal by pregnant women. In 2 cases children were HIV-infected. Both cases were registered before 2004. In both cases no ARV was used, delivery was performed vaginally and children received infant feeding. In addition, in one case HIV status of the child could not be determined due to loss of follow-up.
In case of other 12 pregnancies women received AZT in about the 28th week of pregnancy. During delivery they received one tablet of NVP or i.v. AZT. Caesarean section was performed in all cases. Newborns received NVP in combination with AZT. They were fed by infant formula or breast. No case of HIV transmission to child was recorded in this group.
In 32 cases pregnant women received full prophylactic therapy and all children were negative for HIV infection. Among this group 2 women refused caesarean section.
Of 6 women admitted to IDACIRC after the 28th week of pregnancy only 1 child was born infected. In this case pregnant woman was admitted in the 3rd trimester of pregnancy with the late stage of HIV infection ( Table 4) .
As of December 2007, 5 women are still pregnant. Three of them receive ARV prophylaxis with AZT+3TC+SQV/rtv. Two women are under 28 weeks of gestational age. Total number of HIV-exposed newborns was 58 from 57 deliveries. In one case twins were born. Totally 46 children were HIV-negative. 3 children were identified as HIV-positive. One child died before HIV investigation. Status of one child is undetermined because of lost of follow-up. HIV status of 7 children is under investigation (Table 5) .
No (%)

DISCUSSION
Over the last several years the national response to AIDS in Georgia attracted significant attention. Implementation of nationwide programme on PMTCT should be regarded as another major step towards universal access universal access of to HIV prevention, treatment, care and support along with the achievement of universal coverage with ART. All services are implemented in compliance with universal access of basic principles, implying that services have to be equitable, accessible, affordable, comprehensive and sustainable over the long-term (13) .
Provision of comprehensive packages of PMTCT services in Georgia has been shown to minimize the risk of vertical transmission. As described above none of the women completing full course of ARV prophylaxis, combined with appropriate infant feeding, transmitted HIV to their children.
PMTCT programmes are indisputably the main entry point not only for HIV-related care and treatment for women, but also for other comprehensive care and prevention.
Although most of the pregnant women were infected through heterosexual contacts, majority of them acquired infection from their IDU partner. In Eastern European countries, with more mature epidemics and high prevalence in injecting drug users, sexual transmission from users to non-injecting sexual partners has long been the dominant mode of heterosexual transmission (14) . This interpretation is very important as it confirms that as in early years, Georgia's HIV epidemic was driven by IDU (15, 16) . At the same time, female sexual partners of IDU may serve as bridging population for expansion of HIV epidemic. Implementation of universal access to PMTCT in Georgia along with preventive interventions targeting IDUs can serve as key element for halting spread of the infection from population at risk to general public and avoiding wide-scale epidemic in the country. Death in infancy 1 (1.7)
Premature delivery (before 37 weeks of gestation) 6 (10.3)
Low birth weight (<2,500 g) 8 (13.8) 
